Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 11911449 Albumin-free botulinum toxin formulations

Patent 11911449 was granted and assigned to Revance Therapeutics, Inc. on February, 2024 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity

Currently, there are no issues on this topic.

Find more entities like US Patent 11911449 Albumin-free botulinum toxin formulations

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
By using this site, you agree to our Terms of Service.